ProAssurance (PRA) nears merger completion as most regulators approve deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
ProAssurance Corporation provided an update on its pending merger with The Doctors Company. The merger agreement calls for Jackson Acquisition Corporation, a subsidiary of The Doctors Company, to merge with ProAssurance, leaving ProAssurance as a wholly owned subsidiary.
Shareholders previously approved the merger-related proposals, and U.S. antitrust review under the Hart-Scott Rodino Act was cleared through early termination of the waiting period. As of June 2, 2026, The Doctors Company has received final insurance regulatory approvals in Alabama, the District of Columbia, Illinois, Missouri, Pennsylvania, Texas, Vermont, Lloyd’s of London, and the Cayman Islands Monetary Authority, while review in California remains pending.
The company notes that the timing of California’s decision is uncertain and outside its control, but, based on progress toward satisfying closing conditions, it continues to anticipate closing the transaction by June 30, 2026. The filing also includes extensive forward-looking statement cautions outlining risks that could cause actual outcomes to differ.
Positive
- None.
Negative
- None.
Insights
Most regulatory approvals are in place for ProAssurance’s sale, with California still pending.
The update shows ProAssurance advancing toward completion of its merger with The Doctors Company. Insurance regulators in multiple U.S. jurisdictions, Lloyd’s of London, and the Cayman Islands Monetary Authority have granted final approvals, which are key closing conditions.
However, review by California insurance regulators remains pending, and the company states the timing and outcome are not within its control. Management nonetheless continues to anticipate closing by June 30, 2026, highlighting confidence but also reliance on a single remaining approval.
The detailed forward-looking statement section emphasizes risks typical for large insurance mergers: potential delays, higher costs, business disruption, stock price volatility, possible litigation, and the chance the merger could be terminated with a termination fee. Subsequent company filings will clarify whether California approval is obtained and whether closing occurs as anticipated by June 30, 2026.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Shareholder approval date: June 24, 2025
HSR early termination date: July 2, 2025
Status as of update: June 2, 2026
+1 more
4 metrics
Shareholder approval date
June 24, 2025
Special meeting where merger-related proposals were approved
HSR early termination date
July 2, 2025
FTC granted early termination of Hart-Scott Rodino waiting period
Status as of update
June 2, 2026
Date as of which most insurance approvals had been obtained
Targeted merger closing date
June 30, 2026
Company’s anticipated date to close the merger
Key Terms
Agreement and Plan of Merger, Hart-Scott Rodino Antitrust Improvements Act of 1976, reciprocal inter-insurance exchange, forward-looking statements, +1 more
5 terms
Agreement and Plan of Merger financial
"ProAssurance entered into an Agreement and Plan of Merger with The Doctors Company"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Hart-Scott Rodino Antitrust Improvements Act of 1976 regulatory
"the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976"
A U.S. law that requires companies planning large mergers or acquisitions to notify federal antitrust regulators and observe a waiting period so authorities can review the deal for competition concerns. Think of it like asking a neighborhood committee for permission and time to check before two households combine: the review can delay, modify, or block a transaction, so investors watch HSR filings closely because they affect deal timing, completion risk, and potential value changes.
reciprocal inter-insurance exchange financial
"The Doctors Company, a California-domiciled reciprocal inter-insurance exchange"
forward-looking statements regulatory
"contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
termination fee financial
"circumstance that could give rise to the termination of the merger, including in circumstances requiring ProAssurance to pay a termination fee"
A termination fee is a payment required if one party ends a contract before its agreed-upon end date. It acts like a penalty or compensation to the other party for canceling early, similar to a fee you might pay for breaking a lease or canceling a service contract. For investors, it matters because it can influence a company's decisions and financial obligations related to ending agreements prematurely.
UNITED STATES | |||||
SECURITIES AND EXCHANGE COMMISSION | |||||
Washington, D.C. 20549 | |||||
FORM | |||||
CURRENT REPORT | |||||
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | |||||
Date of Report (Date of earliest event reported): June 2, 2026 | |||||
 | |||||
(Exact name of registrant as specified in its charter) | |||||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Office ) | (Zip code) | ||||||||||
Registrant’s telephone number, including area code: | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17CFR 240.13e-(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ | |||||
ITEM 8.01 OTHER EVENTS.
As previously disclosed, on March 19, 2025, ProAssurance entered into an Agreement and Plan of Merger (the “Merger Agreement”) with The Doctors Company, a California-domiciled reciprocal inter-insurance exchange, and Jackson Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of The Doctors Company (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into ProAssurance (the “Merger”). ProAssurance will continue as the surviving corporation in the Merger as a wholly owned subsidiary of The Doctors Company. The Board has approved the Merger Agreement and the transactions contemplated thereby, including the Merger.
As previously disclosed, on June 24, 2025, ProAssurance held a special meeting of stockholders at which holders of ProAssurance’s common stock approved each of the proposals voted on at the meeting relating to the transactions contemplated by the Merger Agreement. On July 2, 2025, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 with respect to the Merger.
The closing of the proposed Merger remains subject to other customary closing conditions, including approval from insurance regulators in the jurisdictions where the Company’s operating subsidiaries are domiciled. As of June 2, 2026, The Doctors Company has received final approval from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, Pennsylvania, Texas and Vermont. The Company has also obtained final approval from Lloyd’s of London with respect to PRA Corporate Capital Ltd., and from the Cayman Islands Monetary Authority with respect to Inova Re and Eastern Re, each of which is a licensed entity in the Cayman Islands. Review of the proposed Merger by insurance regulators remains pending in California. The timing for completion of the pending review is uncertain and not within the Company’s control, but in light of progress made toward satisfaction of closing conditions, the Company continues to anticipate closing the transaction by June 30, 2026.
FORWARD-LOOKING STATEMENTS
This current report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “hope,” “hopeful,” “likely,” “may,” “optimistic,” “possible,” “potential,” “preliminary,” “project,” “should,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others: (a) the completion of the merger on the anticipated terms and timing, (b) the satisfaction of other conditions to the completion of the merger, including obtaining required regulatory approvals; (c) the risk ProAssurance’s stock price may fluctuate during the pendency of the merger and may decline if the merger is not completed; (d) potential litigation relating to the merger that could be instituted against ProAssurance or its directors, managers or officers, including the effects of any outcomes related thereto; (e) the risk that disruptions from the merger will harm ProAssurance’s business, including current plans and operations, including
2
during the pendency of the merger; (f) the ability of ProAssurance to retain and hire key personnel; (g) the diversion of management’s time and attention from ordinary course business operations to completion of the merger and integration matters; (h) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; (i) legislative, regulatory and economic developments; (j) potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that could affect ProAssurance’s financial performance; (k) certain restrictions during the pendency of the merger that may impact ProAssurance’s ability to pursue certain business opportunities or strategic transactions; (l) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, outbreaks of war or hostilities or global pandemics, as well as management’s response to any of the aforementioned factors; (m) the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (n) unexpected costs, liabilities or delays associated with the transaction; (o) the response of competitors to the transaction; (p) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger, including in circumstances requiring ProAssurance to pay a termination fee; and (q) other risks set forth under the heading “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent filings with the SEC. You should not rely upon forward-looking statements as predictions of future events. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 2, 2026
| PROASSURANCE CORPORATION | ||
| by: /s/ Jeffrey P. Lisenby | ||
| ----------------------------------------------------- | ||
| Jeffrey P. Lisenby General Counsel | ||
3
FAQ
What merger is ProAssurance (PRA) currently involved in?
ProAssurance is pursuing a merger with The Doctors Company, where Jackson Acquisition Corporation will merge into ProAssurance. After completion, ProAssurance will continue as the surviving corporation and become a wholly owned subsidiary of The Doctors Company, subject to satisfaction of all remaining closing conditions.
Which approvals for the ProAssurance (PRA) and The Doctors Company merger have been obtained?
Approvals have been obtained from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, Pennsylvania, Texas, and Vermont. In addition, final approvals were received from Lloyd’s of London for PRA Corporate Capital Ltd. and from the Cayman Islands Monetary Authority for Inova Re and Eastern Re.
Which regulatory approval for the ProAssurance (PRA) merger is still pending?
Regulatory review of the proposed merger by California insurance regulators remains pending. The company notes that the timing for completing this review is uncertain and outside its control, making California the key outstanding regulatory step before the transaction can close as contemplated.
When does ProAssurance (PRA) anticipate closing its merger with The Doctors Company?
ProAssurance continues to anticipate closing the merger by June 30, 2026. This expectation is based on progress toward satisfying closing conditions, including numerous regulatory approvals already obtained, while acknowledging that the remaining California review could affect timing and is beyond the company’s direct control.
What antitrust clearance has the ProAssurance (PRA) merger received?
On July 2, 2025, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. This early termination indicates antitrust review at the federal level was completed without requiring the full statutory waiting period.